CTOs on the Move

CANTEST

www.cantest.com

 
CANTEST Ltd is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cantest.com
  • 4606 Canada Way
    Burnaby, BC CAN V5G 1K5
  • Phone: 925.924.6000

Executives

Name Title Contact Details

Similar Companies

TruHearing

TruHearing works with health plans to offer low out of pocket costs on hearing aids. Ask a Hearing Consultant if your insurance qualifies: 844-319-3988

Bicara

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company`s dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.

Trilogy Behavioral Healthcare

Trilogys Mission is to support people in their recovery from mental illness by helping them discover and reclaim their capabilities and well being.

Breckenridge Pharmaceutical

Breckenridge Pharmaceutical Inc. is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.